What is the latest MARKSANS stock price?
The latest stored price for MARKSANS is Rs 315.30 as of 2026-11-03.
gimli
MARKSANS stock AI analysis
MARKSANS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MARKSANS PHARMA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available MARKSANS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹315.30
1W return
+5.06%
1M return
-3.16%
3M return
+20.23%
6M return
+70.77%
1Y return
+65.62%
Market cap
₹14,288.25 cr
PE
27.65
PB
4.68
ROE
+18.65%
ROCE
+23.06%
RSI
52.36
Turnover
₹24.82 cr
Why it can matter in screens
- Momentum: MARKSANS is below 50DMA, above 200DMA; RSI is 52.36.
- Returns: 1D +0.96%, 1W +5.06%, 1M -3.16%, 3M +20.23%, 1Y +65.62%.
- Trend levels: 52W high ₹350.95, 52W low ₹228.20, off high -10.16%.
- Liquidity: latest turnover is ₹24.82 cr; volume vs 20D is +0.62%.
- Valuation/profitability: PE 27.65, PB 4.68, ROE +18.65%, ROCE +23.06%.
- Growth: 3Y sales CAGR +16.85%, 3Y profit CAGR +16.20%.
Quick Answers
Is MARKSANS above its 50DMA and 200DMA?
MARKSANS is below 50DMA, above 200DMA. The latest 50DMA is 320.60 and the latest 200DMA is 241.27.
What are MARKSANS PE, ROE and ROCE?
MARKSANS has PE 27.65, ROE +18.65%, and ROCE +23.06% in Gimli's latest available snapshot.
How has MARKSANS performed recently?
MARKSANS has returned -3.16% over 1 month, +20.23% over 3 months, and +65.62% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 840.80 cr | 238.44 cr | 157.17 cr | 3.47 |
| 2026-03-31 | 856.11 cr | 230.59 cr | 148.13 cr | 3.27 |
| 2025-12-31 | 754.43 cr | 180.89 cr | 113.20 cr | 2.50 |
| 2025-09-30 | 720.41 cr | 166.06 cr | 98.25 cr | 2.17 |
| 2025-06-30 | 619.99 cr | 105.76 cr | 58.32 cr | 1.29 |
| 2025-03-31 | 708.46 cr | 142.27 cr | 90.55 cr | 2.00 |
| 2024-12-31 | 681.85 cr | 166.41 cr | 104.56 cr | 2.31 |
| 2024-09-30 | 641.92 cr | 146.74 cr | n/a | 2.13 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,950.94 cr | 683.31 cr | 417.90 cr | 9.22 |
| 2025-03-31 | 2,622.84 cr | 599.01 cr | 380.57 cr | 8.40 |
| 2024-03-31 | 2,174.20 cr | 509.00 cr | 313.70 cr | 6.92 |
| 2023-03-31 | 1,849.62 cr | 395.25 cr | 266.31 cr | 6.41 |
| 2022-03-31 | 700.54 cr | 297.68 cr | 103.99 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,860.90 cr | 634.14 cr | 343.38 cr | 3,052.68 cr |
| 2025-03-31 | 3,239.63 cr | 495.79 cr | 321.91 cr | 2,489.38 cr |
| 2024-03-31 | 2,680.95 cr | 403.28 cr | 244.06 cr | 2,085.91 cr |
| 2023-03-31 | 2,190.39 cr | 382.44 cr | 122.94 cr | 1,765.07 cr |
| 2022-03-31 | 1,640.10 cr | 206.41 cr | 110.77 cr | 1,222.97 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 458.12 cr | 327.60 cr | n/a |
| 2025-03-31 | 206.66 cr | 33.74 cr | n/a |
| 2024-03-31 | 230.41 cr | 21.57 cr | n/a |
| 2023-03-31 | 237.41 cr | 183.78 cr | n/a |
| 2022-03-31 | 99.26 cr | 52.93 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +43.87% | +17.47% | +6.19% | +4.36% | +32.47% | +0.00% |
| 2026-03-31 | +43.87% | +16.76% | +6.57% | +4.66% | +32.79% | +0.00% |
| 2025-12-31 | +43.87% | +16.74% | +5.91% | +4.41% | +33.47% | +0.00% |
| 2025-09-30 | +43.87% | +16.92% | +5.28% | +3.92% | +33.93% | +0.00% |
| 2025-06-30 | +43.87% | +19.88% | +5.50% | +3.55% | +30.75% | +0.00% |
| 2025-03-31 | +43.87% | +22.20% | +4.56% | +3.37% | +29.37% | +0.00% |
| 2024-12-31 | +43.87% | +21.96% | +4.30% | +3.15% | +29.87% | +0.00% |
| 2024-09-30 | +43.87% | +21.31% | +4.10% | +3.02% | +30.71% | +0.00% |
| 2024-06-30 | +43.87% | +18.60% | +3.75% | +2.82% | +33.78% | +0.00% |
| 2024-03-31 | +43.85% | +15.57% | +5.17% | +4.23% | +35.40% | +0.00% |
| 2023-12-31 | +43.85% | +15.56% | +4.76% | +3.82% | +35.83% | +0.00% |
| 2023-09-30 | +43.85% | +15.07% | +4.02% | +3.15% | +37.06% | +0.00% |
| 2023-06-30 | +43.85% | +14.91% | +3.65% | +2.79% | +37.59% | +0.00% |
| 2023-03-31 | +43.85% | +15.12% | +1.46% | +0.86% | +39.58% | +0.00% |
| 2023-01-20 | +43.80% | +14.82% | +0.87% | +0.86% | +40.49% | n/a |
| 2022-12-31 | +49.00% | +4.24% | +0.96% | +0.96% | +45.80% | +0.00% |
| 2022-09-30 | +48.60% | +4.06% | +0.95% | +0.95% | +46.38% | +0.00% |
| 2022-06-30 | +48.25% | +0.00% | +4.98% | n/a | n/a | +0.00% |
| 2022-03-31 | +48.25% | +0.00% | +3.93% | n/a | n/a | n/a |
| 2021-12-31 | +48.25% | +0.00% | +3.00% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze MARKSANS PHARMA with valuation, momentum and industry peers
- Compare MARKSANS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare MARKSANS with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.